TY - JOUR
T1 - Characterization of a Human Ovarian Carcinoma Cell Line (NIH
T2 - OVCAR-3) with Androgen and Estrogen Receptors
AU - Hamilton, Thomas C.
AU - Young, Robert C.
AU - McKoy, Wilma M.
AU - Grotzinger, Karen R.
AU - Green, John A.
AU - Whang-Peng, Jacqueline
AU - Rogan, Alfred M.
AU - Ozols, Robert F.
AU - Chu, Elizabeth W.
AU - Green, William R.
PY - 1983/11/1
Y1 - 1983/11/1
N2 - A cell line, NIH:OVCAR-3 has been established from the malignant ascites of a patient with progressive adenocarcinome of the ovary after combination chemotherapy with cyclophosphamide, Adriamycin, and cisplatin. OVCAR-3 grows as a cobble-stone-like monolayer with foci of multilayering, is tumorigenic in athymic mice, clones in agarose, and has an abnormal karyotype which includes a homogeneous staining region and a double minute chromosome. The cultured cells and xenografts contain cytoplasmic androgen and estrogen-binding macromolecules with the specificity of the respective steroid hormone receptors. These components have sedimentation coefficients of 7 to 9S in low-salt sucrose-density gradients, have dissociation constants of 250 and 9.6 pM, and are present at concentrations of 30 and 28 fmol/mg cytosol protein characteristic of androgen and estrogen receptors, respectively. OVCAR-3 is resistant in vitro to clinically relevant concentrations of Adriamycin (5 x 10-8M) melphalan (5 x 10-6M), and cisplatin (5 x 10–7M) with survival compared to untreated controls of 43,45, and 77%, respectively. Furthermore, there are multiple histological similarities between the patient's original tumor, the cell line, and the transplantable tumor. These data indicate that OVCAR-3 may be of use for investigations as to the significance of androgens and estrogens and the mechanisms of cytotoxic drug resistance in ovarian cancer.
AB - A cell line, NIH:OVCAR-3 has been established from the malignant ascites of a patient with progressive adenocarcinome of the ovary after combination chemotherapy with cyclophosphamide, Adriamycin, and cisplatin. OVCAR-3 grows as a cobble-stone-like monolayer with foci of multilayering, is tumorigenic in athymic mice, clones in agarose, and has an abnormal karyotype which includes a homogeneous staining region and a double minute chromosome. The cultured cells and xenografts contain cytoplasmic androgen and estrogen-binding macromolecules with the specificity of the respective steroid hormone receptors. These components have sedimentation coefficients of 7 to 9S in low-salt sucrose-density gradients, have dissociation constants of 250 and 9.6 pM, and are present at concentrations of 30 and 28 fmol/mg cytosol protein characteristic of androgen and estrogen receptors, respectively. OVCAR-3 is resistant in vitro to clinically relevant concentrations of Adriamycin (5 x 10-8M) melphalan (5 x 10-6M), and cisplatin (5 x 10–7M) with survival compared to untreated controls of 43,45, and 77%, respectively. Furthermore, there are multiple histological similarities between the patient's original tumor, the cell line, and the transplantable tumor. These data indicate that OVCAR-3 may be of use for investigations as to the significance of androgens and estrogens and the mechanisms of cytotoxic drug resistance in ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=0021058774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021058774&partnerID=8YFLogxK
M3 - Article
C2 - 6604576
AN - SCOPUS:0021058774
VL - 43
SP - 5379
EP - 5389
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 11
ER -